TriangleASTX727 (NCT03922555)
ASTX727 trial for Recurrent/Progressive Non-Enhancing IDH-Mutant Glioma (NCT03922555). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with IDH mutant gliomas, a type of brain tumor, that have come back or are growing without enhancing on MRI.
The idea: test ASTX727, a pill that combines two drugs, cedazuridine and decitabine. Cedazuridine slows how fast the body breaks down decitabine. It is taken for several days in each 28 day cycle.
This phase 1 study plans 18 patients and looks for the highest dose that can be given safely. At Massachusetts General Hospital in Boston, Isabel Arrillaga-Romany leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.